Toggle Main Menu Toggle Search

Open Access padlockePrints

Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

Lookup NU author(s): Dr Girish Viswanathan, Emerita Professor Sally Marshall, Dr Karthik Balasubramaniam, Professor Azfar Zaman


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow (R). In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean +/- SD, 20,512 +/- 12,567 [n=40] vs. 14,769 +/- 8,531 [n=40] mu m(2)/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean +/- SD, Clopidogrel [n=45]: 13,978 +/- 5,502 to 11,192 +/- 3,764 mu m(2)/mm vs. placebo [n=45]: 13,959 +/- 7,038 to 14,201 +/- 6,780 mu m(2)/mm, p<0.001, delta values: clopidogrel vs. placebo, mean +/- SD, 2,786 +/- 4,561 vs. -249 +/- 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow (R) (cut-off PRUz value of >= 240). Importantly, no correlation was observed between thrombus area and VerifyNow (R) values (rho 0.08, 13=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area +/- SD: 12,186 +/- 4,294 vs. 10,438 +/- 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

Publication metadata

Author(s): Viswanathan GN, Marshall SM, Schechter CB, Balasubramaniam K, Badimon JJ, Zaman AG

Publication type: Article

Publication status: Published

Journal: Thrombosis and Haemostasis

Year: 2012

Volume: 108

Issue: 5

Pages: 937-945

Print publication date: 01/11/2012

ISSN (print): 0340-6245

ISSN (electronic):

Publisher: Schattauer GmbH


DOI: 10.1160/TH12-06-0408


Altmetrics provided by Altmetric


Funder referenceFunder name
department of Cellular Pathology, Newcastle-upon-Tyne Hospital NHS Foundation Trust
department of Haematology Newcastle-upon-Tyne Hospital NHS Foundation Trust
7338Northumberland, Tyne and Wear Comprehensive Local Research Network (CLRN)
BHF/033/07British Heart Foundation
FS/033/07British Heart Foundation (BHF), UK
UKCRN 5159Northumberland, Tyne and Wear Comprehensive Local Research Network (CLRN)